27 May Page 1 of PRODUCT MONOGRAPH. BRILINTA® ticagrelor tablets. 60 and 90 mg. Platelet Aggregation Inhibitor. AstraZeneca Canada Inc. 27 May This leaflet is part III of a three-part “Product. Monograph” published when BRILINTA® was approved for sale in Canada and is designed. Official health care professional site for BRILINTA® (ticagrelor) tablets, indicated to reduce the rate of CV death, MI, BRILINTA® (ticagrelor) [package insert].

Author: Kekasa Tojarg
Country: Uzbekistan
Language: English (Spanish)
Genre: Life
Published (Last): 19 April 2015
Pages: 285
PDF File Size: 8.66 Mb
ePub File Size: 17.5 Mb
ISBN: 142-8-54230-663-3
Downloads: 55623
Price: Free* [*Free Regsitration Required]
Uploader: Kajitilar

FDA Internet Application Site (Accessdata) Error

Do not take new medicines that brilinta package insert aspirin. Food and Drug Administration. Tell your doctor about all the medicines you take, including prescription and over-the-counter brilints, vitamins, and herbal supplements.

Patients were excluded if they required renal dialysis, had a brilints intracranial hemorrhage, had gastrointestinal bleeding within 6 months, had a known bleeding diathesis or coagulation disorder, or required treatment with anticoagulants. People who are treated with brilinta package insert stent, and stop taking BRILINTA too soon, have a higher risk of getting brilinta package insert blood clot in the stent, having a heart attack, or dying.

Mechanism of Action Ticagrelor and its major metabolite reversibly interact with the platelet P2Y12 ADP-receptor to prevent signal transduction and platelet activation. Your doctor can decide what treatment is needed.

Accessdata Error

Instances of serious bleeding, such as internal bleeding, may require blood transfusions or surgery. The authors make no claims of the accuracy of the information contained herein; and these suggested doses are not a substitute for clinical judgment. N Inserg J Med. Patients were excluded if they had a previous intracranial hemorrhage, gastrointestinal bleeding within 6 months, had a known brilinta package insert diathesis or coagulation disorder, or required treatment with anticoagulants.

Long-term use of ticagrelor brilinta package insert patients with prior myocardial infarction.

This site complies with the HONcode standard for trustworthy health information: These can be fatal. You are encouraged to report negative side effects of prescription drugs to the FDA.

BRILINTA is used with aspirin to lower your chance of having another serious problem with your heart or blood vessels such as heart attack, stroke, or blood clots in your stent if you received one. Consider use brilinta package insert a parenteral brilinta package insert in ACS patients requiring co-administration. Bleeding will also take longer than usual to stop.

BRILINTA™ (ticagrelor) tablets

Medical Calculators – A thru Z. The difference between treatments was driven by CV death and MI with no difference in stroke. After one year administer 60 mg twice daily. Only the mg dose strength is approved for use in patients with a history of MI 1 year after an ACS event. Patients were treated for brilintx brilinta package insert 12 months and up to 48 months with a median follow-up time of 33 months. Call your doctor if you have new or unexpected shortness of breath or any side effect that bothers you or that does not go away.

Strong brilinta package insert substantially increase ticagrelor exposure and so increase the risk of adverse events.

Avoid maintenance doses of aspirin above mg daily. Bradyarrhythmias including Brilinta package insert block have been reported in bripinta post-marketing setting. After any initial dose, use with aspirin mg per day.

Strong inducers substantially reduce ticagrelor exposure and so iinsert the efficacy of ticagrelor As with other oral P2Y 12 inhibitors, co-administration of opioid agonists delay and reduce the absorption of ticagrelor.

Consider the risks and benefits of treatment, noting the probable increase in exposure to ticagrelor. In patients treated with PCI, it also reduces the rate of stent thrombosis.

Share With a Friend

Administer 90 mg twice daily during the first year after an ACS event. Log In Search Go.

For at least the first brilinta package insert months following ACS, it is superior to clopidogrel. BRILINTA has been shown to reduce the rate of a combined endpoint of cardiovascular death, myocardial infarction or stroke compared to clopidogrel. Patients with prior MI treated up to 48 months 1,3.